Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The Receivables Turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by average Accounts Receivable. An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. Asia Green Biotechnology's Revenue for the
three
months ended in Sep. 2024 was C$0.00 Mil. Asia Green Biotechnology's average Accounts Receivable for the
three
months ended in Sep. 2024 was C$0.00 Mil.
Asia Green Biotechnology (XCNQ:ASIA) Receivables Turnover Explanation
An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. This metric is commonly used to compare companies within the same industry to check whether they are on par with their competitors.
Asia Green Biotechnology Receivables Turnover Related Terms
Asia Green Biotechnology Receivables Turnover Historical Data
* Premium members only.
The historical data trend for Asia Green Biotechnology's Receivables Turnover can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Asia Green Biotechnology Receivables Turnover Chart
For the Drug Manufacturers - Specialty & Generic subindustry, Asia Green Biotechnology's Receivables Turnover, along with its competitors' market caps and Receivables Turnover data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Asia Green Biotechnology Receivables Turnover vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Asia Green Biotechnology's Receivables Turnover distribution charts can be found below:
* The bar in red indicates where Asia Green Biotechnology's Receivables Turnover falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Asia Green Biotechnology (XCNQ:ASIA) has a Receivables Turnover of 0.00 as of Sep. 2024. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Asia Green Biotechnology and its competitors.
Is Asia Green Biotechnology's Receivables Turnover too high?
Asia Green Biotechnology's current Receivables Turnover is 0.00.
How does Asia Green Biotechnology's Receivables Turnover compare to ZTS?
Asia Green Biotechnology's Receivables Turnover of 0.00 can be compared against companies in the Drug Manufacturers industry. The industry median Receivables Turnover is 5.08. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Receivables Turnover for a Drug Manufacturers company?
The median Receivables Turnover among Drug Manufacturers companies is 5.08, based on 947 companies in the industry. Companies in the top quartile (top 25%) have a Receivables Turnover significantly above this median, while those in the bottom quartile fall well below. However, Receivables Turnover should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Receivables Turnover mean?
A high Receivables Turnover can signal that a stock is expensive relative to its fundamentals. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Asia Green Biotechnology and its competitors. For the Drug Manufacturers industry, the median Receivables Turnover is 5.08 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Asia Green Biotechnology's current Receivables Turnover is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Asia Green Biotechnology stock overvalued right now?
Asia Green Biotechnology (XCNQ:ASIA) has a current Receivables Turnover of 0.00. The current Receivables Turnover is 0.00. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Receivables Turnover calculated?
Receivables Turnover is calculated from a company's financial statements. For Asia Green Biotechnology (XCNQ:ASIA), the current Receivables Turnover is 0.00 as of Sep. 2024. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Asia Green Biotechnology Corp is an early stage international agri-technology company focused on the development, evaluation, testing, application and, ultimately, supply to the market of proprietary organic hybridization technology and certain products derived from that technology. The core approach of the business is centred on the planting, growth and harvesting of new and valuable strains of hemp and related crops in commercial quantities. The company is developing varieties of hemp with superior growth and production characteristics in the various environments found in the licensed territories.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XCNQ:ASIA has been successfully added to your 
